

CD Bioparticles Launches Locust Bean Gum for Biopharmaceutical Applications

CD Bioparticles has launched a new line of Locust Bean Gum for researchers.

NEW YORK, UNITED STATES, June 15, 2023 /EINPresswire.com/ -- [CD Bioparticles](#), a leading manufacturer and supplier of numerous drug delivery products and services, has launched a new line of [Locust Bean Gum](#) with advanced technical platforms to help scientists advance biopharmaceutical research.

Over the past few decades, researchers have been working on developing delivery systems that can reduce side effects while improving efficacy. Natural polymers are used in a wide range of pharmaceutical formulations, including solid monolithic matrix systems, implants, films, beads, microparticles, nanoparticles, inhalable and injectable systems, as well as viscous liquid and gel formulations. In these dosage forms, polymeric materials serve various functions such as binders, matrix formers, drug release modifiers, coatings, thickeners or tackifiers, stabilizers, disintegrants, solubilizers, emulsifiers, suspending agents, gelling agents and bioadhesives.

Due to the specificity of Locust Bean Gum (LBG) and its gelling ability along with synergistic effects with other polysaccharides, there is an increasing interest in its application in biopharmaceuticals. LBG is a neutral polysaccharide composed of mannose and galactose units and is a galactomannan. It is extracted from the seeds of the carob tree (*Ceratonia siliqua*), which is abundant in the Mediterranean region, although its distribution also extends to various parts of North Africa, South America and Asia. There are several synonyms for this polysaccharide, such as such as carob bean gum, carob seed gum, carob flour, or even ceratonia.

LBG is utilized in the development of several drug delivery systems such as tablets, capsules, beads, microspheres, gels and polymer films. LBG-based formulations exhibit sustained release patterns and in a few formulations LBG also has mucoadhesive properties. CD Bioparticles now offers Locust Bean Gum to help researchers and scientists overcome the challenges they face in developing delivery systems.

CD Bioparticles provides customers with biocompatible drug delivery systems, including a variety of biodegradable polymers such as Dextrans, Chitosans, Deparins, and Alginates. These polymers help researchers overcome a variety of obstacles such as lengthy chemical synthesis and purification, limited material selection for additive manufacturing precision medicine, unpredictable or uncontrollable degradation rates of drug-carrying cargoes, and denaturation of

biomolecules during binding.

Together with these biodegradable polymers, this new line of Locust Bean Gum will provide customers with a wide range of benefits, including broad coverage of the functionalized biomolecules useful for customized conjugation, modification, and crosslinking applications, precise formulation of the polymer components to control the degradation time for different drug delivery and bio-graft applications, and diverse solidification of the materials for additive manufacturing of precision medicine.

For more information about CD Bioparticles' new line of Locust Bean Gum, please visit <https://www.cd-bioparticles.net/locust-bean-gum>.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Richard J. Gray

CD Bioparticles

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/639596643>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.